BioPorto A/S announced the release of its 2025 Annual Report on March 26, 202631.
Preliminary unaudited 2025 financials:
Total revenue DKK 40.3 million (11% growth YoY), NGAL revenue DKK 28.2 million (22% growth), adjusted EBITDA loss of DKK 77 million14.
Q4 2025 revenue:
DKK 11.6 million (47% growth YoY), driven by NGAL RUO in the US and strategic distributors14.
2026 guidance:
Total NGAL revenue expected to grow 20-50% to DKK 33-42 million, targeting +60 active US hospitals14.
US market progress:
44 active hospitals by end-2025 (up from 36 in 2024), focusing on children's hospitals and RUO sales14.
Sources:
1. https://www.biospace.com/press-releases/bioporto-provides-preliminary-unaudited-2025-financial-figures-financial-guidance-for-2026-and-a-business-update
3. https://bioporto.com/investor-relations/announcements/
4. https://www.globenewswire.com/news-release/2026/02/05/3233390/0/en/BioPorto-provides-Preliminary-Unaudited-2025-Financial-Figures-Financial-Guidance-for-2026-and-a-Business-Update.html